Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

The purpose of the study is to determine whether the addition of Elotuzumab to Bortezomib/ Dexamethasone will prolong the time before myeloma worsens [progression free survival (PFS)].


Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized Study of Bortezomib/Dexamethasone With or Without Elotuzumab in Subjects With Relapsed/Refractory Multiple Myeloma
Enrollment: 185
Study Start Date: November 2011
Estimated Study Completion Date: April 2016
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)

Arms:
- Experimental: Arm A: Elotuzumab + Bortezomib + Dexamethasone
- Active Comparator: Arm B: Bortezomib + Dexamethasone